BioLife Solutions To Acquire SciSafe

BioLife Solutions, Inc today announced it has entered into a definitive agreement to acquire SciSafe, a privately held multi-facility provider of biological materials storage to the cell and gene therapy and pharmaceutical industries. The transaction is expected to close on September 30th.

SciSafe had 2019 unaudited revenue of $6 million and positive EBITDA and is anticipated to be accretive during 2021.

Under the terms of the agreement, BioLife will pay $15 million in cash and $15 million in newly issued shares of BioLife common stock for 100% of the outstanding shares of SciSafe. SciSafe’s shareholders are also eligible over the next four years to receive up to 626,000 additional shares of BioLife common stock based on the achievement of annual revenue milestones.

Mike Rice, Chief Executive Officer of BioLife Solutions, commented, “This acquisition enables BioLife to offer even more value to our cell and gene therapy customers through an established business with an excellent reputation, marquee customers and seasoned team. Through SciSafe, we are accelerating profitable growth by expanding into the high growth biostorage segment with a robust quality system, a scalable business model and strong financial performance. We anticipate several vertical integration cost synergies including using SciSafe facilities for cGMP storage of our biopreservation media products, leveraging our CBS facility to manufacture walk-in freezer rooms for SciSafe and deploying our evo® Smart Shippers and evoIS cloud app for the thousands of annual inbound and outbound biologic materials shipments managed by SciSafe.”

Garrie Richardson, President of SciSafe, remarked, “I’m thrilled to be joining forces with BioLife. With BioLife’s stellar reputation in the cell and gene therapy market, key customer relationships, financial resources and commitment to fund our growth, the SciSafe team is poised to deliver significant high-margin incremental revenue to BioLife’s growing enterprise.”

Benefits of the Transaction

Entry into the fast-growing biostorage segment

  • SciSafe is well positioned to participate in this growth with four cGMP-compliant facilities located in New Jersey, Massachusetts and Utah, and an aggressive expansion plan focused on the cell and gene therapy clusters located throughout the world.
  • Current SciSafe customers include several Top Five global pharmaceutical companies.  

Cross-selling opportunities

  • BioLife intends to fully leverage its relationships with leading cell and gene therapy companies to drive sales of SciSafe’s suite of biologic storage services.
  • BioLife also intends to fully leverage SciSafe customers with BioLife’s full portfolio of class-defining bioproduction tools including CryoStor® and HypoThermosol® biopreservation media, ThawSTAR® automated thawing products, the evo® cold chain management system and CBS freezers.

Potential vertical integration cost synergies

  • BioLife intends to leverage its Custom Biogenic Systems manufacturing facility to construct walk-in freezer rooms for SciSafe facilities.
  • SciSafe brings the potential for offsite storage of BioLife’s cGMP preservation media products in SciSafe’s cGMP biostorage facilities.
  • BioLife plans to leverage its evo platform and Smart Shippers for inbound and outbound shipments of SciSafe customer’s biologic materials.

Financial Impact of SciSafe Acquisition

BioLife expects the acquisition of SciSafe to impact the Company’s financial performance as follows:

  • Expected fourth quarter 2020 revenue contribution of $1.8 million.
  • Expected 2021 revenue contribution of $9 million.
  • Expected to be accretive to adjusted net income beginning in 2021.

Related Posts

Subscribe Our Newsletter